Systemic T Cell Subsets and Cytokines in Patients With Homozygous Sickle Cell Disease and Asymptomatic Urinary Tract Infections in Togo

REFERENCES

1. 1.↵
   1. Williams NT

   . Sickle cell disease in Sub-Saharan Africa. Hematol Oncol Clin North Am. 2016;30(2):343-358. doi: 10.1016/j.hoc.2015.11.005

   OpenUrlCrossRef
2. 2.↵
   1. Piel FB,
   2. Steinberg MH,
   3. Rees DC

   . Sickle cell disease. N Engl J Med. 2017;376(16):1561-1573. doi: 10.1056/NEJMra1510865

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Segbena AY,
   2. Kueviakoe IMD,
   3. Messie AK

   . Situation de la drepanocytose au Togo. J Rech Sci Univ. 2005;7(1).
4. 4.↵
   1. Bandeira ICJ,
   2. Rocha LBS,
   3. Barbosa MC,
   4. et al.

   Chronic inflammatory state in sickle cell anemia patients is associated with HBB(*)S haplotype. Cytokine. 2014;65(2):217-221. doi: 10.1016/j.cyto.2013.10.009

   OpenUrlCrossRef
5. 5.↵
   1. Pitanga NT,
   2. Vilas-Boas W,
   3. Cerqueira BAV,
   4. et al.

   Cytokine profiles in sickle cell anemia: pathways to be unraveled. Adv Biosci Biotechnol. 2013;4:6-12. doi: 10.4236/abb.2013.47A1002

   OpenUrlCrossRef
6. 6.↵
   1. Makis AC,
   2. Hatzimichael EC,
   3. Bourantas KL

   . The role of cytokines in sickle cell disease. Ann Hematol. 2000;79(8):407-413. doi: 10.1007/s002770000173

   OpenUrlCrossRefPubMedWeb of Science
7. 7.
   1. Keikhaei B,
   2. Mohseni AR,
   3. Norouzirad R,
   4. et al.

   Altered levels of pro-inflammatory cytokines in sickle cell disease patients during vaso-occlusive crises and the steady state condition. Eur Cytokine Netw. 2013;24(1):45-52. doi: 10.1684/ecn.2013.0328

   OpenUrlCrossRef
8. 8.↵
   1. Lanaro C,
   2. Franco-Penteado CF,
   3. Albuqueque DM,
   4. Saad STO,
   5. Conran N,
   6. Costa FF

   . Altered levels of cytokines and inflammatory mediators in plasma and leukocytes of sickle cell anemia patients and effects of hydroxyurea therapy. J Leukoc Biol. 2009;85(2):235-242. doi: 10.1189/jlb.0708445

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Booth C,
   2. Inusa B,
   3. Obaro SK

   . Infection in sickle cell disease: a review. Int J Infect Dis. 2010;14(1):e2-e12.

   OpenUrlCrossRefPubMedWeb of Science
10. 10.↵
    1. Chemegni BC,
    2. Bamzok EKO,
    3. Sack FN,
    4. Ngouadjeu E,
    5. Mbanya D

    . Morbidité et mortalité chez les patients drépanocytaires au Service d’Hématologie de l’Hôpital Central de Yaoundé. Health Sci Dis. 2018.
11. 11.↵
    1. Platt OS,
    2. Brambilla DJ,
    3. Rosse WF,
    4. et al.

    Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med. 1994;330(23):1639-1644. doi: 10.1056/NEJM199406093302303

    OpenUrlCrossRefPubMedWeb of Science
12. 12.↵
    1. Donkor ES,
    2. Osei JA,
    3. Anim-Baidoo I,
    4. Darkwah S

    . Risk of asymptomatic bacteriuria among people with sickle cell disease in Accra, Ghana. Diseases. 2017;5(1):4. doi: 10.3390/diseases5010004

    OpenUrlCrossRef
13. 13.↵
    1. Nath AK,
    2. Hebbel RP

    . Sickle cell disease: renal manifestations and mechanisms. Nat Rev Nephrol. 2015;11(3):161-171. doi: 10.1038/nrneph.2015.8

    OpenUrlCrossRefPubMed
14. 14.↵
    1. Nicolle LE,
    2. Bradley S,
    3. Colgan R,
    4. Rice JC,
    5. Schaeffer A,
    6. Hooton TM

    ; Infectious Diseases Society of America; American Society of Nephrology; American Geriatric Society. Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. Clin Infect Dis. 2005;40(5):643-654. doi: 10.1086/427507. Erratum in Nicolle et al. (2005; 40:643–54). Clin Infect Dis. 2005;40(10):1556. doi: 10.1086/430760

    OpenUrlCrossRefPubMedWeb of Science
15. 15.↵
    1. Ochocinski D,
    2. Dalal M,
    3. Black LV,
    4. et al.

    Life-threatening infectious complications in sickle cell disease: a concise narrative review. Front Pediatr. 2020;8:38. doi: 10.3389/fped.2020.00038

    OpenUrlCrossRef
16. 16.↵
    1. Reygaert WC

    . Innate Immune Response to Urinary Tract Infections Involving Escherichia coli. J Clin Cell Immunol. 2014;5:280.

    OpenUrl
17. 17.↵
    1. Gürgöze MK,
    2. Akarsu S,
    3. Yilmaz E,
    4. et al.

    Proinflammatory cytokines and procalcitonin in children with acute pyelonephritis. Pediatr Nephrol. 2005;20(10):1445-1448. doi: 10.1007/s00467-005-1941-6

    OpenUrlCrossRefPubMed
18. 18.↵
    1. Nguepou Tchopba C,
    2. Katawa G,
    3. Dossim S,
    4. Salou M,
    5. Vovor A,
    6. Ameyapoh YA

    . Asymptomatic urinary tract infections in homozygous sickle cell patients in Togo. Eur J Pharm Med Res. 2020;6(7):44-50.

    OpenUrl
19. 19.↵
    1. Dason S,
    2. Dason JT,
    3. Kapoor A

    . Guidelines for the diagnosis and management of recurrent urinary tract infection in women. Can Urol Assoc J. 2011;5(5):316-322.

    OpenUrlCrossRefPubMed
20. 20.↵
    1. Manuzak J,
    2. Dillon S,
    3. Wilson C

    . Differential interleukin-10 (IL-10) and IL-23 production by human blood monocytes and dendritic cells in response to commensal enteric bacteria. Clin Vaccine Immunol. 2012;19(8):1207-1217. doi: 10.1128/CVI.00282-12

    OpenUrlAbstract/FREE Full Text
21. 21.↵
    1. Katawa G,
    2. Layland LE,
    3. Debrah AY,
    4. et al.

    Hyperreactive onchocerciasis is characterized by a combination of Th17-Th2 immune responses and reduced regulatory T cells. PLoS Negl Trop Dis. 2015;9(1):e3414. doi: 10.1371/journal.pntd.0003414

    OpenUrlCrossRefPubMed
22. 22.↵
    1. Oshiro Y,
    2. Morris DL

    . TNF-alpha release from human peripheral blood mononuclear cells to predict the proinflammatory activity of cytokines and growth factors. J Pharmacol Toxicol Methods. 1997;37(1):55-59. doi: 10.1016/s1056-8719(97)83624-6

    OpenUrlCrossRefPubMed
23. 23.↵
    1. Musa BOP,
    2. Onyemelukwe GC,
    3. Hambolu JO,
    4. Mamman AI,
    5. Isa AH.

    Pattern of serum cytokine expression and T-cell subsets in sickle cell disease patients in vaso-occlusive crisis. Clin Vaccine Immunol. 2010;17(4):602-608. doi: 10.1128/CVI.00145-09

    OpenUrlAbstract/FREE Full Text
24. 24.↵
    1. Torres LS,
    2. Okumura JV,
    3. Silva DGH,
    4. et al.

    Inflammation in sickle cell disease: differential and down-expressed plasma levels of annexin A1 protein. PLoS One. 2016;11(11):e0165833. doi: 10.1371/journal.pone.0165833

    OpenUrlCrossRef
25. 25.↵
    1. McLellan LK,
    2. Hunstad DA

    . Urinary tract infection: pathogenesis and outlook. Trends Mol Med. 2016;22(11):946-957. doi: 10.1016/j.molmed.2016.09.003

    OpenUrlCrossRefPubMed
26. 26.↵
    1. Brousse V,
    2. Buffet P,
    3. Rees D

    . The spleen and sickle cell disease: the sick(led) spleen. Br J Haematol. 2014;166(2):165-176. doi: 10.1111/bjh.12950

    OpenUrlCrossRefPubMed
27. 27.↵
    1. Abraham SN,
    2. Miao Y

    . The nature of immune responses to urinary tract infections. Nat Rev Immunol. 2015;15(10):655-663. doi: 10.1038/nri3887

    OpenUrlCrossRefPubMed
28. 28.↵
    1. Nielubowicz GR,
    2. Mobley HLT

    . Host-pathogen interactions in urinary tract infection. Nat Rev Urol. 2010;7(8):430-441. doi: 10.1038/nrurol.2010.101

    OpenUrlCrossRefPubMed
29. 29.↵
    1. Kak G,
    2. Raza M,
    3. Tiwari BK

    . Interferon-gamma (IFN-γ): exploring its implications in infectious diseases. Biomol Concepts. 2018;9(1):64-79. doi: 10.1515/bmc-2018-0007

    OpenUrlCrossRefPubMed
30. 30.↵
    1. Jones-Carson J,
    2. Balish E,
    3. Uehling DT

    . Susceptibility of immunodeficient gene-knockout mice to urinary tract infection. J Urol. 1999;161(1):338-341.

    OpenUrlCrossRefPubMedWeb of Science
31. 31.↵
    1. Chen L,
    2. Deng H,
    3. Cui H,
    4. et al.

    Inflammatory responses and inflammation-associated diseases in organs. Oncotarget. 2017;9(6):7204-7218. doi: 10.18632/oncotarget.23208

    OpenUrlCrossRefPubMed
32. 32.↵
    1. Murphy K,
    2. Weaver C,
    3. Supérieur DB

    , ed. Masson PL, trans. Immunobiologie de Janeway. 4th ed. 2018.
33. 33.↵
    1. Mege JL,
    2. Meghari S,
    3. Honstettre A,
    4. Capo C,
    5. Raoult D

    . The two faces of interleukin 10 in human infectious diseases. Lancet Infect Dis. 2006;6(9):557-569. doi: 10.1016/S1473-3099(06)70577-1

    OpenUrlCrossRefPubMedWeb of Science
34. 34.↵
    1. Siransy LK,
    2. Yapo-Crézoit CCA,
    3. Diane KM,
    4. et al.

    Th1 and Th2 cytokines pattern among sickle cell disease patients in Côte d’Ivoire. J Clin Immunol Res. 2018. doi: 10.33425/2639-8494.1011

    OpenUrlCrossRef
35. 35.↵
    1. Wensky A,
    2. Marcondes MC,
    3. Lafaille JJ

    . The role of IFN-gamma in the production of Th2 subpopulations: implications for variable Th2-mediated pathologies in autoimmunity. J Immunol. 2001;167(6):3074-3081. doi: 10.4049/jimmunol.167.6.3074

    OpenUrlAbstract/FREE Full Text
36. 36.↵
    1. Aziz N

    . Measurement of circulating cytokines and immune-activation markers by multiplex technology in the clinical setting: what are we really measuring? For Immunopathol Dis Therap. 2015;6(1-2):19-22. doi: 10.1615/ForumImmunDisTher.2015014162

    OpenUrlCrossRef
37. 37.↵
    1. Bhat KH

    1. Kumar V

    . Macrophages: the potent immunoregulatory innate immune cells. In: Bhat KH, ed. Macrophage Activation: Biology and Disease. IntechOpen; 2020:1-30.
38. 38.↵
    1. Fitzgerald KA,
    2. Rowe DC,
    3. Barnes BJ,
    4. et al.

    LPS-TLR4 signaling to IRF-3/7 and NF-kappaB involves the toll adapters TRAM and TRIF. J Exp Med. 2003;198(7):1043-1055. doi: 10.1084/jem.20031023

    OpenUrlAbstract/FREE Full Text
39. 39.↵
    1. Sanin DE,
    2. Prendergast CT,
    3. Mountford AP

    . IL-10 production in macrophages is regulated by a TLR-driven CREB-mediated mechanism that is linked to genes involved in cell metabolism. J Immunol. 2015;195(3):1218-1232. doi: 10.4049/jimmunol.1500146

    OpenUrlAbstract/FREE Full Text
40. 40.↵
    1. Allali S,
    2. Maciel TT,
    3. Hermine O,
    4. de Montalembert M

    . Innate immune cells, major protagonists of sickle cell disease pathophysiology. Haematologica. 2020;105(2):273-283. doi: 10.3324/haematol.2019.229989

    OpenUrlAbstract/FREE Full Text
41. 41.↵
    1. Mäkelä SM,
    2. Strengell M,
    3. Pietilä TE,
    4. Österlund P,
    5. Julkunen I

    . Multiple signaling pathways contribute to synergistic TLR ligand-dependent cytokine gene expression in human monocyte-derived macrophages and dendritic cells. J Leukoc Biol. 2009;85(4):664-672. doi: 10.1189/jlb.0808503

    OpenUrlCrossRefPubMedWeb of Science
42. 42.↵
    1. Kragsbjerg P,
    2. Söderquist B,
    3. Holmberg H,
    4. Vikerfors T,
    5. Danielsson D

    . Production of tumor necrosis factor-alpha and interleukin-6 in whole blood stimulated by live Gram-negative and Gram-positive bacteria. Clin Microbiol Infect. 1998;4(3):129-134.

    OpenUrlPubMed
43. 43.↵
    1. Hessle C,
    2. Hanson LA,
    3. Wold AE

    . Interleukin-10 produced by the innate immune system masks in vitro evidence of acquired T-cell immunity to E. coli. Scand J Immunol. 2000;52(1):13-20. doi: 10.1046/j.1365-3083.2000.00741.x

    OpenUrlCrossRefPubMed
44. 44.↵
    1. Lutay N,
    2. Ambite I,
    3. Hernandez JG,
    4. et al.

    Bacterial control of host gene expression through RNA polymerase II. J Clin Invest. 2013;123(6):2366-2379. doi: 10.1172/JCI66451

    OpenUrlCrossRefPubMed
45. 45.↵
    1. Kamanaka M,
    2. Kim ST,
    3. Wan YY,
    4. et al.

    Expression of interleukin-10 in intestinal lymphocytes detected by an interleukin-10 reporter knockin tiger mouse. Immunity. 2006;25(6):941-952. doi: 10.1016/j.immuni.2006.09.013

    OpenUrlCrossRefPubMedWeb of Science
46. 46.↵
    1. Kalampokis I,
    2. Yoshizaki A,
    3. Tedder TF

    . IL-10-producing regulatory B cells (B10 cells) in autoimmune disease. Arthritis Res Ther. 2013;15 Suppl 1(Suppl 1):S1. doi: 10.1186/ar3907

    OpenUrlCrossRefPubMed
47. 47.↵
    1. Salvador E,
    2. Wagenlehner F,
    3. Köhler CD,
    4. et al.

    Comparison of asymptomatic bacteriuria Escherichia coli isolates from healthy individuals versus those from hospital patients shows that long-term bladder colonization selects for attenuated virulence phenotypes. Infect Immun. 2012;80(2):668-678. doi: 10.1128/IAI.06191-11

    OpenUrlAbstract/FREE Full Text